Neobe Therapeutics

Neobe Therapeutics is a private, pre-clinical stage biotech leveraging synthetic biology to create engineered live biotherapeutics (LBPs) for cancer. Its core platform focuses on designing 'microbial trojan horses' to disrupt the immunosuppressive tumour microenvironment, particularly in immune-excluded solid tumours, to unlock the efficacy of immunotherapies. The company, based in Cambridge, UK, has raised seed funding and collaborates with academic partners to advance its research towards the clinic.

Synthetic biology platform for engineering programmable live biotherapeutics (bacteria) designed as 'microbial trojan horses' to target and remodel the tumour microenvironment, with the goal of overcoming immune exclusion and enabling immunotherapy success in solid tumours.

Competes in the tumour microenvironment modulation space, which includes companies developing enzymes, antibodies, and cell therapies to break down fibrotic barriers or reprogram immunosuppressive signals. Direct competitors using engineered bacterial vectors include other private biotechs like GenCirq, 3T Biosciences, and certain academic spin-outs.